The high degree of association between CSF and PET measurements of SV2A in individuals with AD and the significant reductions in AD compared to CN participants provides support for a novel CSF assay for SV2A that may serve as an additional biomarker for synaptic density in AD. The gene discussed is SV2A; the disease is Alzheimer disease.